You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An IGF-1R-targeting peptide drug conjugate for targeted treatment of atypical teratoid/rhabdoid tumors

    SBC: NIGHTHAWK BIOSCIENCES, INC.            Topic: 102

    PROJECT SUMMARY Atypical teratoid/rhabdoid tumors (AT/RT) are rare embryonal central nervous system malignancies that occur in early childhood and are lethal. Current treatment strategies for children diagnosed with AT/RT are limited to surgery, radiation, and chemotherapy, but to date, none of these have successfully improved survival beyond 18 months, and most are associated with significant tox ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. CN-105 Improves Functional Outcome After Intracranial Hemorrhage

    SBC: AegisCN LLC            Topic: 106

    Annually, approximately 100,000 patients in the USA suffer from intracerebral hemorrhage (ICH), which is associated with high mortality rates and poor long-term cognitive and physical recovery. At present, no pharmacological therapies have been demonstrated to improve functional outcomes after ICH. However, we have successfully demonstrated that CN-105, a pentapeptide derived from the receptor bin ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development ofsynthetic heparin to protect liver graft from ischemia reperfusion injury duringtransplantation

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: NCI

    Project Summary/Abstract According to the most recent data published by the Global Cancer Observatory, over 900,000 patients worldwide were diagnosed with liver cancer in 2020. For patients with hepatocellular carcinoma, the most common type of liver cancer, liver transplantation is the only potentially curative treatment option. Liver transplantation inevitably involves periods of time where the ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Sulfated Carbohydrates for the Treatment of Periodontitis

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: NIDCR

    Abstract Periodontitis affects over half of the American population and has no reliable form of treatment for any stage and grade of the disease besides antibiotics, tooth root scaling and planing and periodontal surgery with highly variable outcomes. This STTR application proposes to identify a structurally defined sulfated low molecular weight heparan sulfate as a novel therapeutic for treatment ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Addressing bone marrow lesions that compromise osteochondral tissue repair

    SBC: Cytex Therapeutics, Inc.            Topic: NIAMS

    ABSTRACT Degenerative joint diseases such as osteoarthritis (OA) remain the source of significant pain and disability, affecting over 30 million adults with an annual US economic burden of more than $486 billion. Joint replacement is a well-established procedure, but its finite life span makes this treatment unacceptable for younger (under 65) or more active individuals. For this growing patient p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. THERAPY FOR ALCOHOL USE DISORDER

    SBC: ARTIAM BIO INC.            Topic: 150

    Abstract Alcohol use disorder (AUD) is a major global health issue. In the US, AUD affects over 14 million people over the age of 18. While there are three approved drugs for AUD, less than 4% of patients eligible for pharmacotherapy are prescribed a medication – likely due to limited efficacy of currently approved agents. Also, the relapse rate for AUD continues to be exceedingly high. Thus, ne ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Improving parent-adolescent communication about sexual and reproductive health

    SBC: Teen Health Research, Inc.            Topic: NICHD

    PROJECT SUMMARY Early adolescence, between the ages of 10-13, is a critical time for sexuality development. It is a period when most young people enter puberty and have new questions about bodies, relationships, and sexual activity. However, the majority of US adolescents enter this early adolescent period without access to the kind of inclusive, comprehensive sex education that could help them de ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. ARRAY: A novel polymeric mesh for prophylactic antibiotic protection of cardiac implantable electronic devices

    SBC: 21MedTech LLC            Topic: NHLBI

    PROJECT SUMMARY 21MedTech, LLC is developing the ARRAYTM antibiotic-loaded envelope to address the need for novel methods to tackle rising rates of infections associated with cardiovascular implantable electronic devices (CIEDs). There were 1.5 million CIEDs implanted in 2011 and that number continues to grow. Between 1% and 4% of implantations result in infection, which have potential for severe ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Novel recombinant sensors to study histone ubiquitin signaling

    SBC: Epicypher, Inc.            Topic: 400

    PROJECT SUMMARYMonoubiquitination (Ub) of histones is an important post-translational modification (PTM) that regulates multiple DNA-related processes including DNA replication, transcription, and repair. Aberrant regulation of histone Ub is strongly linked to the pathogenesis of diverse diseases, including cancer, aging, and inflammation. However, the ability to map the distribution and dynamics ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a sensitive method to measure heparan sulfate 6-O-endosulfatase

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: 300

    The proposal is aimed to develop a sensitive method to measure the activity of heparan sulfate 6-O-endosulfatase (SULF). SULF is an enzyme that removes the 6-O-sulfo groups from heparan sulfate polysaccharides to modulate the functions of heparan sulfate. Evidence has demonstrated that the level of SULF contributes to the progression of cancers; however, the method that measures the activity from ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government